This VJHemOnc podcast highlights key advances in hematopoietic stem cell transplantation from the EBMT 2026 Annual Meeting, spanning graft-versus-host disease (GvHD) management, donor selection, and evolving clinical strategies. Mohamad Mohty, MD, PhD, Sorbonne University and Hôpital Saint-Antoine, Paris, France, discusses novel approaches in acute and chronic GvHD, including microbiome-based therapies and targeted agents.

Carmelo Gurnari, MD, Cleveland Clinic, Cleveland, OH, explores germline predisposition and its implications for donor selection and transplant decision-making. Anna Sureda, MD, Institut Català d’Oncologia, Barcelona, Spain, reviews transplant strategies in Hodgkin lymphoma, while Alexandros Spyridonidis, MD, University of Patras, Patras, Greece, discusses the role of measurable residual disease (MRD) in guiding transplant decisions alongside evolving strategies in the era of CAR T-cell therapy.